Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions ...

Panelists discuss how real-world evidence comparing apalutamide and abiraterone, including the impact of prednisone use, informs balanced and patient-specific first-line treatment choices. Panelists ...

New Delhi: The Subject Expert Committee (SEC) on Oncology, under the Central Drugs Standard Control Organisation (CDSCO), has recommended the grant of permission to MSN Laboratories Private Limited ...

Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone ...

Objectives: To compare the efficacy and safety of three drugs—Apalutamide, Abiraterone, and Bicalutamide—combined with Androgen Deprivation Therapy (ADT) in patients with metastatic hormone-sensitive ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a company of Johnson & Johnson (NYSE:JNJ), reported applying to the European ...

Aim: To identify factors predicting primary resistance to new-generation hormonal agents (NHAs), abiraterone acetate and enzalutamide in patients with castration-resistant prostate cancer (CRPC).

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC. “Improvements in rPFS are supported by a statistically significant ...